Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0.7%

Novo Nordisk A/S (NYSE:NVOGet Free Report) shares were down 0.7% on Monday . The company traded as low as $127.45 and last traded at $127.50. Approximately 1,050,855 shares changed hands during trading, a decline of 80% from the average daily volume of 5,162,833 shares. The stock had previously closed at $128.40.

Analyst Ratings Changes

Several research firms have weighed in on NVO. UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.25.

Get Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Trading Up 0.4 %

The stock has a market capitalization of $569.87 billion, a price-to-earnings ratio of 47.19, a PEG ratio of 2.11 and a beta of 0.41. The business’s 50-day simple moving average is $123.47 and its two-hundred day simple moving average is $107.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.35 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is presently 49.17%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several large investors have recently made changes to their positions in the company. Cornerstone Planning Group LLC acquired a new position in Novo Nordisk A/S during the second quarter worth $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Novo Nordisk A/S by 165.3% during the 1st quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock worth $32,000 after acquiring an additional 124 shares during the last quarter. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $26,000. Pacific Center for Financial Services grew its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Finally, Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $28,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.